Pharma Nostra

pharmanostra.com.br

A Pharma Nostra® é uma empresa científica, voltada para a pesquisa e desenvolvimento, que tem como carro-chefe a inovação, qualidade e comprometimento com o setor magistral. Durante a sua trajetória, a Pharma Nostra® consolidou-se como especialista no tratamento individualizado, isso porque a marca compreende cada ser humano como único e, com base em suas necessidades específicas, permite tornar qualquer fórmula sob medida e multidisciplinar.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

REVISION THERAPEUTICS, INC. ANNOUNCES LICENSE WITH CORNELL TO DEVELOP TREATMENT FOR STARGARDT DISEASE

reVision | September 01, 2020

news image

reVision Therapeutics, Inc. ("reVision" or the "Company"), a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular and rare diseases, today announced that it has signed an exclusive license agreement with Cornell University ("Cornell") for the development and commercialization of Cornell's proprietary technology for the treatment of Stargardt disease, a genetic disorder that affe...

Read More

BUSINESS INSIGHTS

NEXTRNA LAUNCHES WITH $56 MILLION IN FUNDING TO BRING TRANSFORMATIVE NON-CODING RNA-DIRECTED MEDICINES TO PATIENTS

NextRNA Therapeutics | March 02, 2022

news image

NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop transformative therapeutics, announces its launch with $9.3 million in seed financing and a $46.8 million Series A led by Cobro Ventures and Lightchain Capital, with additional participation from Circle Alternative Investments, Evans Capital, Jefferies, Rivas Capital, and Willett Advisors. Proceeds will be used by the company to augment its target and drug discovery engine, expand its pipeline, an...

Read More

APHA: TRANSPARENCY, SAFETY AND AVAILABILITY MUST BE CORE PRINCIPLES FOR STRENGTHENING AMERICA'S DRUG SUPPLY CHAIN

APhA | August 11, 2020

news image

The reliability, quality and safety of our nation's drug supply chain are essential to the nation's security and health and well-being of the American public. Therefore, we welcome comprehensive federal efforts to improve the state of our drug supply chain, particularly at a time when our health care system is under extraordinary stress. The President's Executive Order last week, "Ensuring Essential Medicines, Medical Countermeasures and Critical Inputs Are Made in the United St...

Read More

OPEN ORPHAN SECURES STUDY TRIAL CONTRACT WITH MYSTERY PHARMACEUTICAL COMPANY

Open Orphan | August 10, 2020

news image

Pharmaceutical services company Open Orphan has scored a £4.0m contract with an unnamed top-three global pharmaceutical company to be the sponsor of and provide a respiratory syncytial virus human challenge study trial. Open Orphan said the new contract represented the continued conversion of its substantial pipeline and generation of significant cash flow. The AIM-listed group added that the study would take place in subsidiary hVIVO's London-based quarantine unit and was expected to ...

Read More
news image

REVISION THERAPEUTICS, INC. ANNOUNCES LICENSE WITH CORNELL TO DEVELOP TREATMENT FOR STARGARDT DISEASE

reVision | September 01, 2020

reVision Therapeutics, Inc. ("reVision" or the "Company"), a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular and rare diseases, today announced that it has signed an exclusive license agreement with Cornell University ("Cornell") for the development and commercialization of Cornell's proprietary technology for the treatment of Stargardt disease, a genetic disorder that affe...

Read More
news image

BUSINESS INSIGHTS

NEXTRNA LAUNCHES WITH $56 MILLION IN FUNDING TO BRING TRANSFORMATIVE NON-CODING RNA-DIRECTED MEDICINES TO PATIENTS

NextRNA Therapeutics | March 02, 2022

NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop transformative therapeutics, announces its launch with $9.3 million in seed financing and a $46.8 million Series A led by Cobro Ventures and Lightchain Capital, with additional participation from Circle Alternative Investments, Evans Capital, Jefferies, Rivas Capital, and Willett Advisors. Proceeds will be used by the company to augment its target and drug discovery engine, expand its pipeline, an...

Read More
news image

APHA: TRANSPARENCY, SAFETY AND AVAILABILITY MUST BE CORE PRINCIPLES FOR STRENGTHENING AMERICA'S DRUG SUPPLY CHAIN

APhA | August 11, 2020

The reliability, quality and safety of our nation's drug supply chain are essential to the nation's security and health and well-being of the American public. Therefore, we welcome comprehensive federal efforts to improve the state of our drug supply chain, particularly at a time when our health care system is under extraordinary stress. The President's Executive Order last week, "Ensuring Essential Medicines, Medical Countermeasures and Critical Inputs Are Made in the United St...

Read More
news image

OPEN ORPHAN SECURES STUDY TRIAL CONTRACT WITH MYSTERY PHARMACEUTICAL COMPANY

Open Orphan | August 10, 2020

Pharmaceutical services company Open Orphan has scored a £4.0m contract with an unnamed top-three global pharmaceutical company to be the sponsor of and provide a respiratory syncytial virus human challenge study trial. Open Orphan said the new contract represented the continued conversion of its substantial pipeline and generation of significant cash flow. The AIM-listed group added that the study would take place in subsidiary hVIVO's London-based quarantine unit and was expected to ...

Read More